StockMarketWire.com - SalvaRx Group said a date had been set in January for a vote on the sale of a key subsidiary to Canada's Portage Biotech.

Portage shareholders would vote on 8 January to approve SalvaRx's sale of its 94% stake in SalvaRx Limited.

'The company will now finalise and publish its shareholder circular and a further announcement will be made by the company in due course,' SalvaRx.


At 1:09pm: [LON:SALV] Salvarx Group Plc share price was +2.5p at 64.25p



Story provided by StockMarketWire.com